Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Eko Launches SENSORA Cardiac Disease Detection Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Daiichi Sankyo, GAIA Partner on Lipodia...

Pharmaceutical companies are increasingly integrating digital health tools with...

Medtronic Expands Strategic Alliance with GE...

Medtronic has entered into a multi-year renewal and significant...

UK Medical Device Testing Jumps 17%,...

Clinical investigations of medical devices in the UK reached...

Eko announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI which objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.

SENSORA™ is a cardiovascular disease detection platform combining the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope. By capturing and analysing heart sounds and electrical signals with its digital stethoscopes.

The FDA-cleared SENSORA™ structural murmur detection helps health systems more accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with the primary care physician. VHD is a life-threatening condition diagnosed in more than 8 million Americans. VHD, when left undetected and untreated, can lead to heart failure, stroke, blood clots, and death. Older adults have a 1 in 10 chance of developing clinically significant VHD. However, more than half (57%) of clinically significant valvular heart disease goes undetected in this population. A primary care physician using SENSORA™ for structural murmur detection more than doubles likelihood of detecting significant VHD.

 

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

Daiichi Sankyo, GAIA Partner on Lipodia Digital Therapeutics

Pharmaceutical companies are increasingly integrating digital health tools with...

Medtronic Expands Strategic Alliance with GE HealthCare

Medtronic has entered into a multi-year renewal and significant...

UK Medical Device Testing Jumps 17%, AI and Neurotech Lead

Clinical investigations of medical devices in the UK reached...

Medtronic Secures FDA PMA for Infuse Bone Graft in TLIF

Medtronic announced that it has secured FDA premarket approval...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »